01.09.22|Itay Barnea“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
22.09.20|CTechCTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D
22.09.20|Meir OrbachProceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy